Combined treatment with dipeptidyl peptidase 4 (DPP4) inhibitor sitagliptin and elemental diets reduced indomethacin-induced intestinal injury in rats via the increase of mucosal glucagon-like peptide-2 concentration

Journal of Clinical Biochemistry and Nutrition

Volumn 56, Issue 2, 2015, Pages 155-162

  Fujiwara, Kaori ^a   Inoue, Takuya ^a   Yorifuji, Naoki ^a   Iguchi, Munetaka ^a   Sakanaka, Taisuke ^a   Narabayashi, Ken ^a   Kakimoto, Kazuki ^a   Nouda, Sadaharu ^a   Okada, Toshihiko ^a   Ishida, Kumi ^a   Abe, Yosuke ^a   Masuda, Daisuke ^a   Takeuchi, Toshihisa ^a   Fukunishi, Shinya ^a   Umegaki, Eiji ^a   Akiba, Yasutada ^b   Kaunitz, Jonathan D ^b   Higuchi, Kazuhide ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

DPP4; DPP8; GLP 1; GLP 2; Sitagliptin

Indexed keywords

GLUCAGON LIKE PEPTIDE 2; INDOMETACIN; MESSENGER RNA; SITAGLIPTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; ELEMENTAL DIET; ENZYME ACTIVITY; ENZYME INHIBITION; GASTROINTESTINAL MUCOSA; ILEUM; INTESTINE ULCER; JEJUNUM; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; SCORING SYSTEM; ULCER HEALING; UPREGULATION;

RATTUS;

EID: 84924987716     PISSN: 09120009     EISSN: None     Source Type: Journal    
DOI: 10.3164/jcbn.14-111     Document Type: Article

References (34)

1. Reimer MK, Holst JJ, Ahrén B. Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice. Eur J Endocrinol 2002; 146: 717-727.
2. Frezza EE, Wachtel MS, Chiriva-Internati M. The multiple faces of glucagonlike peptide-1-obesity, appetite, and stress: what is next? A review. Dig Dis Sci 2007; 52: 643-649.
3. Takasaki K, Takada H, Nakajima T, Ueno K, Ushiki J, Higo K. Involvement of the active metabolites in the inhibitory activity of K579 on rat plasma dipeptidyl peptidase IV. Eur J Pharmacol 2004; 505: 237-241.
4. Takasaki K, Nakajima T, Ueno K, Nomoto Y, Higo K. Effects of combination treatment with dipeptidyl peptidase IV inhibitor and sulfonylurea on glucose levels in rats. J Pharmacol Sci 2004; 95: 291-293.
5. Dubé PE, Brubaker PL. Frontiers in glucagon-like peptide-2: multiple actions, multiple mediators. Am J Physiol Endocrinol Metab 2007; 293: E460-E465.
6. Drozdowski L, Thomson ABR. Intestinal hormones and growth factors: effects on the small intestine. World J Gastroenterol 2009; 15: 385-406.
7. Hartmann B, Thulesen J, Kissow H, et al. Dipeptidyl peptidase IV inhibition enhances the intestinotrophic effect of glucagon-like peptide-2 in rats and mice. Endocrinology 2000; 141: 4013-4020.
8. Boushey RP, Yusta B, Drucker DJ. Glucagon-like peptide 2 decreases mortality and reduces the severity of indomethacin-induced murine enteritis. Am J Physiol 1999; 277: E937-E947.
9. Jeppesen PB, Sanguinetti EL, Buchman A, et al. Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients. Gut 2005; 54: 1224-1231.
10. Yazbeck R, Howarth GS, Abbott CA. Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease? Trends Pharmacol Sci 2009; 30: 600-607.
11. Hildebrandt M, Rose M, Rüter J, Salama A, Mönnikes H, Klapp BF. Dipeptidyl peptidase IV (DP IV, CD26) in patients with inflammatory bowel disease. Scand J Gastroenterol 2001; 36: 1067-1072.
12. Xiao Q, Boushey RP, Cino M, Drucker DJ, Brubaker PL. Circulating levels of glucagon-like peptide-2 in human subjects with inflammatory bowel disease. Am J Physiol Regul Integr Comp Physiol 2000; 278: R1057-R1063.
13. Geier MS, Tenikoff D, Yazbeck R, McCaughan GW, Abbott CA, Howarth GS. Development and resolution of experimental colitis in mice with targeted deletion of dipeptidyl peptidase IV. J Cell Physiol 2005; 204: 687-692.
14. Liu X, Murali SG, Holst JJ, Ney DM. Enteral nutrients potentiate the intestinotrophic action of glucagon-like peptide-2 in association with increased insulin-like growth factor-I responses in rats. Am J Physiol Regul Integr Comp Physiol 2008; 295: R1794-R1802.
15. Fisher M, Knappertz V. The dose of aspirin for the prevention of cardiovascular and cerebrovascular events. Curr Med Res Opin 2006; 22: 1239-1248.
16. Berger JS, Brown DL, Becker RC. Low-dose aspirin in patients with stable cardiovascular disease: A meta-analysis. Am J Med 2008; 121: 43-49.
17. Higuchi K, Umegaki E, Watanabe T, et al. Present status and strategy of NSAIDs-induced small bowel injury. J Gastroenterol 2009; 44: 879-888.
18. Ito Y, Sasaki M, Funaki Y, et al. Nonsteridal anti-inflammatory druginduced visible and invisible small intestinal injury. J Clin Biochem Nutr 2013; 53: 55-59.
19. Handa O, Naito Y, Fukui A, Omatsu T, Yoshikawa T. The impact of nonsteridal anti-inflammatory drug on the small intestinal epithelium. J Clin Biochem Nutr 2014; 54: 2-6.
20. Mizukami K, Murakami K, Hirashita Y, et al. Efficacy of rebamipide for low-dose aspirin-related gastrointestinal symptoms. J Clin Biochem Nutr 2012; 51: 216-220.
21. Wallace JL, Syer S, Denou E, et al. Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. Gastroenterology 2011; 141: 1314-1322.
22. Inoue T, Higashiyama M, Kaji I, et al. Dipeptidyl peptidase IV inhibition prevents the formation and promotes the healing of indomethacin-induced intestinal ulcers in rats. Dig Dis Sci 2014; 59: 1286-1295.
23. O'Moráin C, Segal AW, Levi AJ. Elemental diet as primary treatment of acute Crohn's disease: A controlled trial. Br Med J 1984; 288: 1859-1862.
24. Yamamoto T, Nakahigashi M, Umegae S, Kitagawa T, Matsumoto K. Impact of elemental diet on mucosal inflammation in patients with active Crohn's disease: cytokine production and endoscopic and histological findings. Inflamm Bowel Dis 2005; 11: 580-588.
25. Sahara N, Fukasawa K, Harada M, Suzuki K. Immunohistochemical localization of dipeptidyl peptidase IV in rat digestive organs. Acta Histochem Cytochem 1983; 16: 494-501.
26. Darmoul D, Voisin T, Couvineau A, et al. Regional expression of epithelial dipeptidyl peptidase IV in the human intestines. Biochem Biophys Res Commun 1994; 203: 1224-1229.
27. Wang JH, Inoue T, Higashiyama M, et al. Umami receptor activation increases duodenal bicarbonate secretion via glucagon-like peptide-2 release in rats. J Pharmacol Exp Ther 2011; 339: 464-473.
28. Inoue T, Wang JH, Higashiyama M, et al. Dipeptidyl peptidase IV inhibition potentiates amino acid-and bile acid-induced bicarbonate secretion in rat duodenum. Am J Physiol Gastrointest Liver Physiol 2012; 303: G810-G816.
29. Lambeir AM, Durinx C, Scharpé S, De Meester. Dipeptidyl-peptidase IV from bench to bedside: An update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci 2003; 40: 209-294.
30. Tolhurst G, Reimann F, Gribble FM. Nutritional regulation of glucagon-like peptide-1 secretion. J Physiol 2009; 587: 27-32.
31. Jeppesen PB, Hartmann B, Thulesen J, et al. Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon. Gastroenterology 2001; 120: 806-815.
32. Buchman AL, Katz S, Fang JC, Bernstein CN, Abou-Assi SG; Teduglutide Study Group. Teduglitide, a Novel mucosally active analog of glucagon-like peptide-2 (GLP-2) for the treatment of moderate to severe Crohn's disease. Inflamm Bowel Dis 2010; 16: 962-973.
33. Yu DM, Ajami K, Gall MG, et al. The in vivo expression of dipeptidyl peptidases 8 and 9. J Histochem Cytochem 2009; 57: 1025-1040.
34. Yazbeck R, Sulda ML, Howarth GS, et al. Dipeptidyl peptidase expression during experimental colitis in mice. Inflamm Bowel Dis 2010; 16: 1340-1351.